About STALICLA
STALICLA is a company based in Geneve (Switzerland) founded in 2017 by Lynn Durham.. STALICLA has raised $24.05 million across 5 funding rounds from investors including Addex Therapeutics, European Union and SPRIM Global Investments. STALICLA operates in a competitive market with competitors including Nura Bio, Healx, Cingulate, PaxMedica and Abliva, among others.
- Headquarter Geneve, Switzerland
- Founders Lynn Durham
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.05 M (USD)
in 5 rounds
-
Latest Funding Round
$2.5 M (USD), Series B
Jun 30, 2025
-
Investors
Addex Therapeutics
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of STALICLA
STALICLA has successfully raised a total of $24.05M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $2.5 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $2.5M
-
First Round
First Round
(05 Feb 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Series B - STALICLA | Valuation | Addex Therapeutics |
|
| Jan, 2024 | Amount | Debt – Conventional - STALICLA | Valuation |
investors |
|
| Jan, 2024 | Amount | Series B - STALICLA | Valuation | SPRIM Global Investments |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in STALICLA
STALICLA has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Addex Therapeutics, European Union and SPRIM Global Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
SPRIM Global Investments is focused on funding life science innovations.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Oral small molecules for neurological disorders are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by STALICLA
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - STALICLA
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stalicla Comparisons
Competitors of STALICLA
STALICLA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nura Bio, Healx, Cingulate, PaxMedica and Abliva, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| domain | founded_year | HQ Location |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| domain | founded_year | HQ Location |
Drugs for neurodevelopmental disorders are developed by PaxMedica.
|
|
| domain | founded_year | HQ Location |
Drugs are developed to treat multiple neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stalicla
Frequently Asked Questions about STALICLA
When was STALICLA founded?
STALICLA was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is STALICLA located?
STALICLA is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Who is the current CEO of STALICLA?
Lynn Durham is the current CEO of STALICLA. They have also founded this company.
Is STALICLA a funded company?
STALICLA is a funded company, having raised a total of $24.05M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $3.8M, raised on Feb 05, 2020.
What does STALICLA do?
STALICLA was established in 2017 in Geneva, Switzerland, within the biotechnology sector focused on precision medicine. Neurodevelopmental disorders are addressed through the companys manufacturing operations. The DEPI technology platform is employed to advance the pipeline candidate STP7, a multifaceted mGluR5 negative allosteric modulator. This candidate is directed toward cocaine abuse treatment and various other neurological indications, supporting targeted therapeutic development.
Who are the top competitors of STALICLA?
Who are STALICLA's investors?
STALICLA has 3 investors. Key investors include Addex Therapeutics, European Union, and SPRIM Global Investments.